SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal Activity and Favorable Safety Profile of SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple …
 
       
       
       
       
  
 
     
     
     
     
     
     
     
     
     
     
     
    